Cagrilintide
Also called CagriSema, Cagrilintide-semaglutide
Educational only, not medical advice. Dosaly reports what has been studied; it isn't a recommendation to use Cagrilintide or any amount of it. Talk to a clinician.
Investigational; not approved as a medicine by the FDA or EMA, alone or combined with semaglutide (as of October 2026).
Research applications
- Weight management on its own (phase 2 trial)
- Combined with semaglutide as CagriSema (phase 3 REDEFINE trials)
- Fullness and stomach emptying (amylin receptor)
What studies have looked at, not proven uses.
What it is
Cagrilintide is an experimental, long-acting version of amylin, a hormone that helps you feel full. It's mostly studied together with semaglutide for weight management.
More detail
Cagrilintide is an investigational long-acting analog of amylin, a hormone released by the pancreas together with insulin that signals fullness and slows stomach emptying. Developed by Novo Nordisk, it carries a fatty-acid chain so that it acts for about a week. A phase 2 trial studied it alone for weight management, but most later research tests it combined with semaglutide, a pairing called CagriSema: phase 3 trials (REDEFINE) in adults with overweight or obesity, with and without type 2 diabetes, were published in 2025. Gastrointestinal side effects were the most commonly reported.
Evidence listed here
- 4 human studies
Results from cells and animals often don't carry over to people. How to read peptide research
Molecular info
- Class
- Lipidated peptide (amylin analog)
- Length
- Based on amylin (37 amino acids)
- Sequence
- Not shown here
- Research areas
- Weight, Metabolic
A modified amylin with a fatty-acid chain that extends its action to about a week.
Research
- Human studyN Engl J Med · 2025Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.
Phase 3 trial (REDEFINE 1) of CagriSema in overweight or obesity.
- Human studyN Engl J Med · 2025Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.
Phase 3 trial (REDEFINE 2) in overweight or obesity with type 2 diabetes.
- Human studyLancet · 2021Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Phase 2 placebo-controlled trial of cagrilintide alone for weight management.
- Human studyLancet · 2021Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Phase 1b randomized trial of cagrilintide given with semaglutide.